BioCentury
ARTICLE | Clinical News

Alla Chem preclinical data

September 2, 2013 7:00 AM UTC

In vitro and in vivo, ONC1-13B led to greater antitumor activity as calculated per unit of concentration in plasma and had a lower potential for drug-drug interactions vs. Xtandi enzalutamide (formerly MDV3100) and ARN-509. Alla Chem said a submission package to begin a Phase I/II trial with ONC1-13B, an androgen receptor antagonist, is under review by Russian Regulatory Agencies. ...